Is Guardant Health (GH) Trading At A Discount To Cash Flow?

Guardant Health has turned into a high profile story in liquid biopsy, and the stock’s very large 3 year gain now puts a spotlight on a simple question for you as an investor. Do the cash flows that Guardant Health can generate over time support a share price of about US$167 today, or has sentiment moved ahead of what the business currently produces in hard dollars?

• Over the past 3 years the share price has delivered a very large gain, which puts a lot of weight on whether the underlying cash generation can keep pace with expectations embedded in that move.
• Fresh approvals for Guardant360 CDx and clinical data on Guardant Reveal can influence how quickly the company turns its testing portfolio into durable revenue and eventually cash flow, as well as how long it may need to keep funding losses and free cash flow burn.
• Prefer to judge Guardant Health on sales? See why Guardant Health's 19.0x P/S tells a different valuation story.

The issue now is whether Guardant Health’s current market value is in line with what its cash flows justify when evaluated using a Discounted Cash Flow (DCF) lens.

If you want a quick reference point for this kind of high-expectation story in liquid biopsy and precision oncology, line Guardant Health up against stocks in the 34 healthcare AI stocks

Is Guardant Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here hinges on Guardant Health turning sizeable cash outflows into sustained inflows over the next decade. Latest twelve month free cash flow is a loss of about $232.9 million, so the whole exercise depends on the testing portfolio scaling enough to flip that figure into positive territory and keep it there.

The projections assume free cash flow recovers and then grows, with estimates pointing to several hundred million dollars of yearly cash generation by 2030 and beyond. Because this DCF output places Guardant Health’s estimated intrinsic worth meaningfully above the current share price of $167.47, the market is treating the business as relatively expensive today on near term losses, yet still not fully reflecting the longer term cash flow profile implied by the model. The recent CE mark for Guardant360 CDx in Europe helps explain why some investors appear willing to look past ongoing free cash flow burn and lean on that longer runway of projected cash generation. Find out what Guardant Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Guardant Health Narrative: What Would Justify Today's Price?

That valuation puzzle around Guardant Health only really becomes useful when you spell out the stories that could sit behind it. Simply Wall St Narratives do exactly that by laying out what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today’s price on the Community page. Each narrative frames fair value as a thesis about Guardant Health's business that you can track over time to see how it holds up against new information.

The community splits on Guardant Health, with one camp seeing more upside left in the story and the other arguing expectations already bite hard.

Bull case: 16% undervalued

"Rapid integration of AI-powered clinical analytics and multi-omic profiling into Guardant's Smart Liquid Biopsy platform is creating new clinical applications, enhancing product utility and differentiation versus peers..."

Discover why this Narrative puts Guardant Health at 16% undervalued.

Bear case: 11% overvalued

"Reliance on premium Medicare ADLT pricing for Shield at US$1,495 and very limited commercial reimbursement means any shift in payer mix toward commercial patients or slower than hoped contracting could compress Shield ASPs and limit revenue growth from screening..."

Explore why this Narrative puts Guardant Health at 11% overvalued.

One more Guardant Health angle that could change the story

Cash flow models only go so far if the people steering Guardant Health are not aligned with you. It is therefore worth checking who is in charge, how they are rewarded, and what that reveals about priorities. See who runs Guardant Health and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com